In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: A possible contribution to lipodystrophy syndrome

Mitochondrion

Volumn 1, Issue 6, 2002, Pages 511-518

  Mukhopadhyay, Abhijit ^a   Wei, Baoxian ^a   Zullo, Steven J ^b,c   Wood, Lauren V ^d   Weiner, Henry ^a  

^a PURDUE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Inhibition; Lipodystrophy; Mitochondria; Protease

Indexed keywords

ALDEHYDE DEHYDROGENASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; CELL PROTEIN; DIMETHYL SULFOXIDE; ENZYME PRECURSOR; INDINAVIR; MITOCHONDRIAL ENZYME; PEPTIDE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG SOLUBILITY; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LIPODYSTROPHY; MAMMAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; YEAST;

HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA;

EID: 0036788642     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-7249(02)00042-9     Document Type: Article

References (33)

1. Adamec, J., Gakh, O., Spizek, J., Kalousek, F., 1999. Complementation between mitochondrial processing peptidase (MPP) subunits from different species. Arch. Biochem. Biophys. 370, 77-85.
2. Berson, A., Fau, D., Fornacciari, R., 2001. Mechanisms for experimental buprenorphine hepatoxicity: major role of mitochondrial dysfunction versus metabolic activation. J. Hepatol. 34, 261-269.
3. Braun, H.P., Schmitz, U.K, 1995. Are the 'core' proteins of the mitochondrial bc1 complex evolutionary relies of a processing protease? Trends Biochem. Sci. 20, 171-175.
4. Brinkman, K., Smeitnik, J.A., Romijn, J.A., Reiss, P., 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354, 1112-1115.
5. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D.J., 1998a. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51-F58.
6. Carr, A., Samaras, K., Chisholm, D.J., Cooper, D.A., 1998b. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 352, 1881-1883.
7. Cote, H.F., Brumme, Z.L., Craib, K.J.P., 2002. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N. Engl. J. Med. 346, 811-820.
8. Fauci, A.S., Bartlett, J.G., Goosby, E.P., Kates, J. (Eds.), 2002. USPHS Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents (http://www.hivatis.org/guidelines/adult/Feb04/AdultGdl.pdf). Revised on line periodically, see http://hivatis.org/trtgdlns.html#Adult.
9. Foli, A., Benvenuto, F., Piccinini, G., 2001. Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 15, 1687-1694.
10. Gaou, I., Malliti, M., Guimont, M.-C., 2001. J. Pharmacol. Exp. Ther. 297, 516-523.
11. Geli, V., 1993. Functional reconstitution in Escherichia coli of the yeast mitochondrial matrix peptidase from its two inactive subunits. Proc. Natl Acad. Sci. USA 90, 6247-6251.
12. Glick, B., Pon, L.A., 1995. Isolation of highly purified mitochondria from Saccharomyces cerevisiae. Methods Enzymol. 260, 213-223.
13. Hammen, P.K., Waltner, M., Hahnemann, B., Heard, T.S., Weiner, H., 1996. The role of positive charges and structural segments in the presequence of rat liver aldehyde dehydrogenase in import into mitochondria. J. Biol. Chem. 271, 21041-21048.
14. Heard, T.S., Weiner, H., 1998. A regional net charge and structural compensation model to explain how negatively charged amino acids can be accepted within a mitochondrial leader sequence. J. Biol. Chem. 273, 29389-29393.
15. Ito, A., 1999. Mitochondrial processing peptidase: multiple-site recognition of precursor proteins. Biochem. Biophys. Res. Commun. 265, 611-616.
16. Jeng, J., Weiner, H., 1991. Purification and characterization of catalytically active precursor of rat liver mitochondrial aldehyde dehydrogenase expressed in Escherichia coli. Arch. Biochem. Biophys. 289, 214-222.
17. Lewis, W., Dalakas, M.C., 1995. Mitochondrial toxicity and antiviral drugs. Nat. Med. 1, 417-422.
18. Luciano, P., Geli, V., 1996. The mitochondrial processing peptidase: function and specificity. Experientia 52, 1077-1082.
19. Mallal, S.A., John, M., Moore, C.B., James, I.R., McKinnon, E.J., 2000. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14, 1309-1316.
20. Martinez, E., Mocroft, A., Garcia-Viejo, M.A., 2001. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357, 592-598.
21. Mauss, S., 2000. HIV-associated lipodystrophy syndrome. AIDS 14, S197-S207.
22. Miro, O., Gomez, M., Pedrol, E., Cardellach, F., Nunes, V., Casademont, J., 2000. Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy-related lipodystrophy. AIDS 14, 1855-1857.
23. Neupert, W., 1997. Protein import into mitochondria. Annu. Rev. Biochem. 66, 863-917.
24. Nolan, D., John, M., Mallal, S., 2001. Antiretroviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antivir. Ther. 6, 145-160.
25. Palella, F., Delaney, K.M., Moorman, A.C., 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860.
26. Roche, R., Poizot-Martina, I., Martin-El Yazidi, C., 2002. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 16, 13-20.
27. Shikuma, C.M., Hu, N., Milne, C., 2001. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 15, 1801-1809.
28. Taylor, A.B., Smith, B.S., Kitada, S., 2001. Crystal structures of mitochondrial processing peptidase reveal the mode for specific cleavage of import signal sequences. Structure 9, 615-625.
29. van der Valk, M., Gisolf, E.H., Reiss, P., 2001. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 15, 847-855.
30. Walker, U.A., Bickel, M., Lutke Volksbeck, S.I., 2002. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J. Acquir. Immune Defic. Syndr. 29, 117-121.
31. Waltner, M., Weiner, H., 1995. Conversion of a nonprocessed mitochondrial precursor protein into one that is processed by the mitochondrial processing peptidase. J. Biol. Chem. 270, 26311-26317.
32. Zaera, M.G., Miro, O., Pedrol, E., 2001. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 15, 1643-1651.
33. Zullo, S.J., Wei, B., Mukhopadhyay, A., Wood, L., Weiner, H., 2001. Inhibition of mitochondrial processing protease by protease inhibitors: a novel mechanism for mitochondrial dysfunction in HAART-associated lipodystrophy. Mitochondrion 1, 105-106.